Gotta disagree. There has been no mention anywhere of a potential for the FDA to extend the shelf life. Besides, if they had why would so many bid this up to $15+ on the release? Definitely not baked in.
Why it tanked after that tremendous response is still difficult to explain. Best I can offer is that it ran up high on volume with the announcement. Some took the initial opportunity to collect profits. After a recovery attempt, more profit-taking wore it down (at the same time the overall market was tanking) and nobody ever jumped in front of the bus again. Result: slow, painful deterioration that pulled more and more retail investors in, continuing the cycle. Troubling that nobody picked it back up as it fell, but somewhat understandable considering the recent strong run.
This does create headwinds for taking it back up and the best action would be an institutional or two seeing the opportunity and bidding it back up to $15. An analyst upgrade could be warranted as well.
I don't have a solid explanation, nobody does, but I'm holding for bigger numbers yet to come.